We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HLN:NYSEHaleon plc Analysis

Data as of 2026-04-08 - not real-time

$9.88

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Haleon plc is trading near its technical support zone with the 20‑day moving average sitting just below the 50‑day average, hinting at a modest bearish tilt. The RSI hovers just under the neutral 50 mark and the MACD histogram has turned slightly positive, suggesting a tentative bullish momentum that could sustain a short‑term bounce. Volatility is elevated, yet the stock’s beta remains very low, indicating limited systematic risk despite market swings. The company delivers a solid dividend yield of around two percent with a comfortable payout ratio, reinforcing its appeal to income‑focused investors. Fundamentals show strong cash generation, healthy margins and a forward‑looking earnings estimate that outpaces the current trailing earnings, though growth is flat and the DCF model flags the current price as above intrinsic value. Analyst consensus remains positive with a “buy” rating and a target price that implies upside potential, while recent earnings commentary highlighted margin improvement but missed revenue growth guidance, adding a note of caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with limited upside
  • Neutral momentum indicators (RSI, MACD)
  • Attractive dividend yield for income

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst consensus and target price suggest upside
  • Improving gross margins and strong cash flow
  • Low beta reduces exposure to market volatility

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustainable dividend with moderate payout ratio
  • Mature consumer‑health business limiting high growth
  • Stable global footprint mitigating geographic concentration

Key Metrics & Analysis

Financial Health

Revenue Growth0.60%
Profit Margin15.11%
P/E Ratio20.2
ROE10.27%
ROA4.67%
Debt/Equity52.37
P/B Ratio4.0
Op. Cash Flow$2.6B
Free Cash Flow$1.4B
Industry P/E25.8

Technical Analysis

TrendNeutral
RSI40.7
Support$9.65
Resistance$10.64
MA 20$10.03
MA 50$10.47
MA 200$9.86
MACDBullish
VolumeStable
Fear & Greed Index84.86

Valuation

Fair Value$2.70
Target Price$12.07
Upside/Downside22.14%
GradeOvervalued
TypeValue
Dividend Yield1.92%

Risk Assessment

Beta0.18
Volatility30.66%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.